Page 227 - Read Online

Sobenin. Vessel Plus 2020;4:18 I http://dx.doi.org/10.20517/2574-1209.2020.09 Page 5 of 6

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993;71:9B-14.
2. Summerhill V, Orekhov A. Pericytes in atherosclerosis. Adv Exp Med Biol 2019;1147:279-97.
3. Orekhov AN, Tertov VV, Novikov ID, Krushinsky AV, Andreeva ER, et al. Lipids in cells of atherosclerotic and uninvolved human
aorta. I. Lipid composition of aortic tissue and enzyme-isolated and cultured cells. Exp Mol Pathol 1985;42:117-37.
4. Orekhov AN. LDL and foam cell formation as the basis of atherogenesis. Curr Opin Lipidol 2018;29:279-84.
5. Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y, et al. Atherosclerotic cardiovascular disease: a review of initiators and protective
factors. Inflammopharmacology 2016;24:1-10.
6. Morita SY. Metabolism and modification of apolipoprotein B-containing lipoproteins involved in dyslipidemia and atherosclerosis. Biol
Pharm Bull 2016;39:1-24.
7. Arnao V, Tuttolomondo A, Daidone M, Pinto A. Lipoproteins in atherosclerosis process. Curr Med Chem 2019;26:1525-43.
8. Nakajima K, Tanaka A. Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis. Clin Chim
Acta 2018;478:200-15.
9. Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. Nat Rev Cardiol
2019;16:727-44.
10. Maguire EM, Pearce SWA, Xiao Q. Foam cell formation: a new target for fighting atherosclerosis and cardiovascular disease. Vascul
Pharmacol 2019;112:54-71.
11. Alipov VI, Sukhorukov VN, Karagodin VP, Grechko AV, Orekhov AN. Chemical composition of circulating native and desialylated low
density lipoprotein: what is the difference? Vessel Plus 2017;1:107-15.
12. Summerhill VI, Grechko AV, Yet SF, Sobenin IA, Orekhov AN. The atherogenic role of circulating modified lipids in atherosclerosis. Int
J Mol Sci 2019;20:E3561.
13. Orekhov AN, Sobenin IA. Modified and dysfunctional lipoproteins in atherosclerosis: effectors or biomarkers? Curr Med Chem
2019;26:1512-24.
14. Orekhov AN, Sobenin IA. Modified lipoproteins as biomarkers of atherosclerosis. Front Biosci (Landmark Ed) 2018;23:1422-44.
15. Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the
pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol 2016;27:473-83.
16. Hurt-Camejo E, Camejo G. ApoB-100 lipoprotein complex formation with intima proteoglycans as a cause of atherosclerosis and its
possible ex vivo evaluation as a disease biomarker. J Cardiovasc Dev Dis 2018;5:E36.
17. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. J
Mol Med (Berl) 2017;95:1153-65.
18. Bäck M, Yurdagul A Jr, Tabas I, Öörni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic
opportunities. Nat Rev Cardiol 2019;16:389-406.
19. Poznyak AV, Wu WK, Melnichenko AA, Wetzker R, Sukhorukov V, et al. Signaling pathways and key genes involved in regulation of
foam cell formation in atherosclerosis. Cells 2020;9:E584.
20. Albany CJ, Trevelin SC, Giganti G, Lombardi G, Scottà C. Getting to the heart of the matter: the role of regulatory T-cells (Tregs) in
cardiovascular disease (CVD) and atherosclerosis. Front Immunol 2019;10:2795.
21. Nasser MI, Zhu S, Huang H, Zhao M, Wang B, et al. Macrophages: first guards in the prevention of cardiovascular diseases. Life Sci
2020;250:117559.
22. Shi X, Gao J, Lv Q, Cai H, Wang F, et al. Calcification in atherosclerotic plaque vulnerability: friend or foe? Front Physiol 2020;11:56.
23. Wang C, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular
senescence. Circ Res 2012;111:245-59.
24. Yao YG, Kajigaya S, Feng X, Samsel L, McCoy JP Jr, et al. Accumulation of mtDNA variations in human single CD34+ cells from
maternally related individuals: effects of aging and family genetic background. Stem Cell Res 2013;10:361-70.
25. Sobenin IA, Chistiakov DA, Bobryshev YV, Postnov AY, Orekhov AN. Mitochondrial mutations in atherosclerosis: new solutions in
research and possible clinical applications. Curr Pharm Des 2013;19:5942-53.
26. Sobenin IA. Mitochondrial DNA damage in atherosclerosis. In: Parine NR, editor. Genetic Polymorphisms. Croatia: InTech; 2017. pp.
139-58.
27. Volobueva A, Grechko A, Yet SF, Sobenin I, Orekhov A. Changes in mitochondrial genome associated with predisposition to
atherosclerosis and related disease. Biomolecules 2019;9:377.
28. Sazonova MA, Ryzhkova AI, Sinyov VV, Sazonova MD, Khasanova ZB, et al. Creation of cultures containing mutations linked with
cardiovascular diseases using transfection and genome editing. Curr Pharm Des 2019;25:693-9.